GT Biopharma, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 09/30/25 | FY 06/30/25 | FY 12/31/24 | FY 12/31/23 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Selling, general & administrative | $8.9M | — | — | $8.6M | $7.1M |
| Research and development | $3.5M | — | — | $5.8M | $6.5M |
| Operating expenses | — | — | — | — | $13.6M |
| Operating income | -$12.4M | — | — | -$14.4M | -$13.6M |
| Interest expense | $127,000 | — | — | — | $213,000 |
| Net income | -$28.4M | — | — | -$13.2M | -$7.6M |
| Balance Sheet | |||||
| Cash and equivalents | $6.8M | — | — | $4.0M | $1.1M |
| Current assets | $8.1M | — | — | $4.2M | $14.1M |
| Total assets | $8.1M | $4.3M | $7.1M | $4.2M | $14.1M |
| Current liabilities | $2.3M | — | — | $5.9M | $6.6M |
| Total liabilities | — | $1.3M | $31.0M | — | $6.6M |
| Stockholders' equity | $5.8M | $3.0M | -$25.9M | -$1.7M | $7.5M |
| Cash Flow Statement | |||||
| Cash from operations | -$12.9M | — | — | -$12.9M | -$8.9M |
| Stock-based compensation | $432,000 | — | — | $230,000 | — |
| Dividends paid | $229,000 | — | — | — | — |
Shares outstanding 36.1M · Free float 98.5%
Annual filing data through FY ended December 31, 2025; float as of July 8, 2026.